NasdaqGS - Nasdaq Real Time Price USD

FibroGen, Inc. (FGEN)

0.3114
-0.0080
(-2.50%)
As of 1:34:05 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
29,621
29,621
46,803
140,734
235,309
Cost of Revenue
15,561
15,561
3,962
20,280
12,871
Gross Profit
14,060
14,060
42,841
120,454
222,438
Operating Expense
145,022
145,022
352,956
421,479
510,968
Operating Income
-130,962
-130,962
-310,115
-301,025
-288,530
Net Non Operating Interest Income Expense
-2,951
-2,951
-501
6,156
-2,153
Other Income Expense
-19,454
-19,454
-12,606
--
--
Pretax Income
-153,367
-153,367
-323,222
-294,869
-290,683
Tax Provision
-269
-269
-252
358
347
Earnings from Equity Interest Net of Tax
--
--
2,638
1,573
1,007
Net Income Common Stockholders
-47,579
-47,579
-284,232
-293,654
-290,023
Diluted NI Available to Com Stockholders
-47,579
-47,579
-284,232
-293,654
-290,023
Basic EPS
-1.23
-0.48
-2.92
-3.14
-3.14
Diluted EPS
-1.23
-0.48
-2.92
-3.14
-3.14
Basic Average Shares
99,462.2500
100,044
97,303
93,582
92,349
Diluted Average Shares
99,462.2500
100,044
97,303
93,582
92,349
Total Operating Income as Reported
-150,416
-150,416
-322,721
-301,025
-288,530
Total Expenses
160,583
160,583
356,918
441,759
523,839
Net Income from Continuing & Discontinued Operation
-47,579
-47,579
-284,232
-293,654
-290,023
Normalized Income
-133,678.1216
-133,678.1216
-310,373.8283
-293,654
-290,023
Interest Income
5,296
5,296
7,594
7,596
--
Interest Expense
8,247
8,247
8,095
1,440
2,153
Net Interest Income
-2,951
-2,951
-501
6,156
-2,153
EBIT
-145,120
-145,120
-315,127
-293,429
-288,530
EBITDA
-142,428
-142,428
-305,197
-282,825
-273,721
Reconciled Cost of Revenue
15,561
15,561
3,962
20,280
12,871
Reconciled Depreciation
2,692
2,692
9,930
10,604
14,809
Net Income from Continuing Operation Net Minority Interest
-153,098
-153,098
-322,970
-293,654
-290,023
Total Unusual Items Excluding Goodwill
-19,454
-19,454
-12,606
0
0
Total Unusual Items
-19,454
-19,454
-12,606
0
0
Normalized EBITDA
-122,974
-122,974
-292,591
-282,825
-273,721
Tax Rate for Calcs
0
0
0
0.0002
0.0003
Tax Effect of Unusual Items
-34.1216
-34.1216
-9.8283
0
0
12/31/2021 - 11/14/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRSN Mersana Therapeutics, Inc.
0.3090
-7.77%
 
SGMO Sangamo Therapeutics, Inc.
0.7270
+1.00%
 
KPTI Karyopharm Therapeutics Inc.
5.97
-2.93%
 
CTMX CytomX Therapeutics, Inc.
1.0250
-5.96%
 
ADCT ADC Therapeutics SA
1.2625
-1.37%
 
GOSS Gossamer Bio, Inc.
1.1300
+0.90%
 
MGNX MacroGenics, Inc.
1.4500
-5.84%
 
APLT Applied Therapeutics, Inc.
0.4002
-2.32%
 
PEPG PepGen Inc.
1.5400
0.00%
 
MBRX Moleculin Biotech, Inc.
1.0402
+2.99%